| Start Date: | 10/5/2022 | Start Time: | 4:00 PM |
| End Date: | 10/5/2022 | End Time: | 5:30 PM |
|
Event Description
BIOMED Seminar
CLICK HERE TO ATTEND VIA ZOOM
Title:
Life Science Innovation Ecosystems: Collaboration and Connections
Speaker:
Matthew Burkhardt
Director
Pennsylvania Biotechnology Center (PABC)
B+labs
Details:
The life science economic sector has experienced several years of rapid expansion due to the advent of novel modalities, supporting technologies, and an influx of capital. Much of this activity and the accompanying financial inflows have been concentrated in geographies that share commonalities. As such, several key variables that drive the success of individuals, institutions and industrial partners, and specific geographic regions are identifiable.
Given his prior activities within the life science industry across academic, Pharma, and startup communities in San Francisco, Boston, and elsewhere, Matthew will discuss his experience with the key variables that drive innovation and sector-specific expansion. Matthew will also comment on the strategic vision for B+labs and the Philadelphia life science community.
Suggested reading: Godfrey, P.C., Allen, G.N. & Benson, D. The biotech living and the walking dead. Nat Biotechnol 38, 132–141 (2020). https://doi.org/10.1038/s41587-019-0399-1
Biosketch:
Matthew graduated from Davidson College with a Liberal Arts degree and post-baccalaureate work in biology, genetics, and physiology at the University of Oregon. He worked under Dr. Elizabeth Blankenhorn at Hahnemann University School of Medicine studying immunogenetics, and under Dr. Kathryn Saatman at University of Pennsylvania’s Neurosurgery Department studying cytoskeletal dynamics after traumatic axonal injury.
Within industry, Matthew has over 15 years’ experience in target and asset discovery at Pharma and startup companies. He began at Merck Research Laboratories (MRL) with in vivo Alzheimer’s Disease small molecule drug discovery and disease model divisions and then moved to iPierian, one of the first companies to use the induced pluripotent stem cell (iPSC) platform. Matthew has held further positions at the Allen Institute for Brain Science, Cellogy, and Novartis. He is currently the Director at B+labs in Philadelphia, an incubation site for companies developing novel medicines across multiple indications.
Matthew has been fortunate to have been involved in three programs that reached clinical stage: the in-licensed Alectos/Merck MK-8719 O-GlcNAcase inhibitor in Progressive Supranuclear Palsy (PSP), the internally developed PSP monoclonal antibody candidate Gosuranemab at iPierian (sold to Bristol-Myers Squibb, 2014), and the internally developed Cold Agglutinin Disease monoclonal antibody Sutimlimab at True North Therapeutics (sold to Bioverativ, 2017; approval Feb. 2022).
More recently, Matthew has been heavily involved in entrepreneurial and innovative company foundation and early operations and strategy in the San Francisco Bay Area and Boston, MA. In addition to his current role at B+labs, Matthew serves as Scientific Advisory Board Chair for the Schinzel-Giedion Syndrome Foundation, a UK-based non-profit patient advocacy organization supporting research and discovery efforts for children with SGS. |
|
Location:
Papadakis Integrated Sciences Building (PISB), Room 120, located on the northeast corner of 33rd and Chestnut Streets. Also on Zoom. |
|
